The ASCO Moment Nobody Predicted

The numbers were already public. What wasn't public — until May 31, 2026 — was what happens when you put those numbers in front of a room full of oncologists who've spent careers watching their patients die on chemo.

Dr. Rachna Shroff of the University of Arizona Cancer Center wasn't even involved in the study. She heard the data from the floor of the ASCO meeting in Chicago and told reporters, "Having treated pancreatic cancer for 16 years, I actually started crying." A doctor doesn't cry at a medical conference over a marginal improvement.

What the Data Actually Says

Daraxonrasib patients in the Phase 3 trial lived a median of 13.2 months versus 6.7 months for patients who received additional chemotherapy, according to findings published in the New England Journal of Medicine and presented at ASCO by Dr. Brian Wolpin of the Dana-Farber Cancer Institute.

That's nearly double. For a cancer that kills roughly 80% of patients at late-stage diagnosis, per NPR's reporting on American Cancer Society data, "nearly double" is not a rounding error. It's the biggest survival improvement this disease has ever seen in the second-line setting.

"New Standard of Care" — That's a Formal Claim Now

Wolpin stood at ASCO and said flatly that daraxonrasib should become "a new standard of care" for previously treated metastatic pancreatic cancer.

That language matters to oncologists. It means Wolpin is telling every cancer center in the country: if you're still putting these patients on salvage chemo, you're behind.

Dr. Zev Wainberg of UCLA, who helped lead the study, added another critical detail: many patients were still on the drug when the data was cut. That means the 13.2-month median survival number may actually be an undercount. The final survival gap, when all patients are tracked to completion, could be wider. According to AP News, Wainberg said the survival gap "may widen as researchers continue tracking them."

The FDA Is Moving Fast

Revolution Medicines — ticker RVMD — funded the study, according to CNBC. The FDA has confirmed it plans to expedite review of the drug. Expanded access is already open for patients who meet certain criteria.

The agency is signaling it understands what's at stake. About 70,000 Americans are diagnosed with pancreatic cancer every year, per NPR, and the five-year survival rate sits at a grim 13%, according to the American Cancer Society. Every month of delay in approval is a month some of those 70,000 people spend on chemotherapy instead of something that works twice as well.

What Comes Next — and Why It Matters

Wolpin told the ASCO audience that researchers will now explore using daraxonrasib earlier in the disease — not just after prior treatments fail. The specific question they're chasing: can tumor shrinkage from this drug make more patients eligible for surgery?

If it works earlier and opens surgical doors, you're talking about a completely different disease trajectory for thousands of patients.

The drug works by blocking a mutated KRAS protein present in more than 90% of pancreatic cancer cases — a target that researchers had been trying to crack for decades. The fact that it finally works, in pill form, with fewer severe side effects than chemo, rewrites decades of research.

Side effects to watch: CNBC notes Wolpin flagged rash — which can be severe — and mouth sores as the most likely issues affecting continued use. But the trial data showed patients stayed on daraxonrasib significantly longer than chemo patients stayed on their regimens. That tells you something about tolerability in the real world.

What Comes After Approval

Every outlet covering this — AP, NPR, CNBC — is leading with "hope" and "promise." Those framings are accurate, but they sidestep the practical question: when does this get approved, and what will it cost? Revolution Medicines is a publicly traded company. Expedited FDA review is moving faster than usual, but "expedited" still means months, not days — and expanded access doesn't reach everyone who needs it. The patients who can't get into a major cancer center, can't navigate the expanded access paperwork, or live in rural America aren't getting this drug yet.

Approval speed and pricing should be the next story. CNBC at least noted the RVMD ticker. Nobody's asked the obvious follow-up: what's this pill going to cost per month?

The Bottom Line

Vicky Stinson, a 65-year-old retired landscape architect from Flagstaff, Arizona, was told she had "months — not years" after her Stage 3 diagnosis in 2024. She's two years in and still hiking, per NPR's May 12 profile. She's already benefiting from daraxonrasib.

Most patients won't have her outcome. But for the first time in decades, oncologists are crying in conference halls. That matters.